Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Arch Therapeutics is raising $7,520,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Terrence Norchi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Arch Therapeutics

The Mission of Arch Therapeutics is to develop products that will improve the lives of patients and enhance the quality of care offered by healthcare personnel. We intend to offer compelling options to healthcare institutions facing limited resources. Arch Therapeutics strives to be a leader in the field of stasis and barrier applications, including hemostasis and sealant products. We intend to develop products with dramatically improved profiles and characteristics over competing products, and we intend to broaden the scope of the field by developing improved solutions to problems beyond the traditional hemostasis and sealant realms.

To learn more about Arch Therapeutics, visit http://www.archtherapeutics.com/

Contact:
Terrence Norchi, President and Chief Executive Officer
617-431-2317
tnorchi@archtherapeutics.com
https://www.linkedin.com/in/terrence-norchi-16529521/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved